Nebivolol
Bystolic
Nebivolol (Bystolic) is a longevity & bioregulators research compound. Highly beta-1 selective blocker that also stimulates nitric-oxide-mediated vasodilation — the only beta blocker with that second mechanism.
Nebivolol quick facts
| Reported research dose | 2.5–10mg daily |
| Route | Oral |
| Frequency | 1x |
| Half-life | ~10 hours (longer in poor CYP2D6 metabolisers) |
| Forms | Oral |
| Evidence level | Approved for hypertension; the favourable metabolic profile rests on smaller trials |
The beta blocker least likely to cause the classic complaints — fatigue, erectile dysfunction, worsened lipids and insulin resistance — because of the NO-mediated vasodilation and the beta-1 selectivity. If a beta blocker is needed in someone who trains, this is usually the one.
How Nebivolol works
Highly beta-1 selective blocker that also stimulates nitric-oxide-mediated vasodilation — the only beta blocker with that second mechanism.
Proposed benefits
Researched for mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
✅ Clinically validated
- Approved for hypertension, with the SENIORS trial (2,128 patients over 70) showing reduced death and cardiovascular hospitalisation in elderly heart failure patients — notably including those with preserved ejection fraction, a group where little else has worked.
- Head-to-head hard-outcome superiority over older beta-blockers has not been demonstrated, despite the favourable mechanism. The metabolic and vasodilatory advantages are real on measurement and unproven on events.
📊 Correlative data
- Widely prescribed, and the beta-blocker most often chosen when the conventional ones cause problems. Less fatigue, less erectile dysfunction and less metabolic disturbance are the consistent real-world reports.
🧪 Theoretical / extrapolated
- The most beta-1 selective beta-blocker available, and it does something no other one does: it stimulates endothelial nitric oxide release through beta-3 activation, producing vasodilation.
- That combination inverts the usual beta-blocker problem. Conventional beta-blockers raise peripheral resistance and worsen insulin sensitivity; adding NO-mediated vasodilation counteracts both.
- High beta-1 selectivity also means minimal beta-2 blockade — the mechanism behind less bronchospasm and less interference with fat mobilisation during training.
These tiers tell you how much human evidence exists — not how well something works. This is the research space, and most of what’s in here is new rather than disproven. Something sitting at “theoretical” usually means nobody has funded the trial, not that the trial was run and failed.
The trap runs the other way too: something can be clinically validated and still do very little for you specifically. A statistically significant result in a study population is not a promise about your body.
- ✅ Clinically validated — human randomised trials or meta-analyses support it. The strongest footing available.
- 📊 Correlative — observational or epidemiological data. Suggestive, and genuinely useful for direction, but it cannot establish cause.
- 🧪 Theoretical / mechanistic — the mechanism is understood and often demonstrated in cells or animals, and the human trial doesn’t exist yet. Unproven is not the same as ineffective. Plenty of what’s standard practice today sat here five years ago.
✗ is a safety flag, not a grade. Where you see it, the concern is harm — not a disappointing trial. A compound tested for one purpose and found not to help there can still be worth studying somewhere else, so a negative result never gets rendered as a cross. It sits alongside the tier, because something can be both well-studied and genuinely risky.
My job is to tell you which one you’re looking at, and let you make the call. Grading something low isn’t me dismissing it — it’s me refusing to oversell it. This is the research space, and being able to reason forward from a mechanism matters as much as waiting for the trial.
Nebivolol — safety, predicted from mechanism
Much of this compound class has never been through a human safety trial. Rather than say nothing — or print a generic warning — this is what its known mechanism predicts could go wrong, and what you can do about it. Predictions are labelled as predictions.
What the mechanism predicts
Derived from what this molecule does, not from a trial.
- These are short peptide fragments of organ extracts, and the honest starting point is that the mechanism itself is not established in a way that lets anyone predict harm precisely. The proposal is gene-regulatory — short peptides binding DNA and modulating transcription in a tissue-specific way. If that is what they do, the theoretical concern is influencing transcription in tissue you were not aiming at.
- In practice the doses are tiny, the peptides are short, and they are degraded quickly — which is also the argument that they may do very little at all. Those two possibilities are the same uncertainty viewed from opposite ends, and you should hold both.
What has actually been reported
- Decades of Russian clinical use with a strikingly clean tolerability record — injection-site reactions and little else reported.
- That record comes almost entirely from one research school, is largely unreplicated outside it, and safety data from a group with an interest in the outcome is worth less than the same data from a sceptic. This is not an accusation; it is how evidence weighting works.
How to reduce the risk
Each of these follows from the same mechanism as the prediction.
- Follow the course printed on the label rather than running continuously. These are the one class in the Vault where a duration is STATED rather than inferred, and it is typically 10–20 days repeated a few times a year. Read the box.
- Run one at a time. They are cheap and it is tempting to stack six. If something changes, a stack of six tells you nothing about which one did it — and given the evidence base, attribution is the entire value of your own experiment.
- Decide your endpoint before you start, and make it a marker or a measurable symptom rather than a feeling. With a compound class this under-evidenced, an unfalsifiable endpoint means you will conclude it worked no matter what happened.
- Buy from a source that publishes third-party testing. Where the molecule itself is uncertain, identity and purity are the only variables you can actually control.
What it does to your bloodwork
A fact about the assay, not a guess about the drug.
- Test the ORGAN, not the peptide. A thymic peptide is judged on immune markers, a pineal one on sleep and IGF-1, a vascular one on lipids and inflammatory markers. There is no assay for the compound itself.
Don't run this if
- Pregnancy — not because of a specific finding, but because nobody has studied it and the mechanism claim is transcriptional.
- Active malignancy, on the same reasoning as any tissue-growth signal: unproven, mechanistically arguable, and not worth finding out.
The honest unknown
- Essentially everything a sceptic would want: independent replication, pharmacokinetics, and whether the oral forms survive digestion at all. Unproven is not the same as ineffective — but here it is a large unproven.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Where to get Nebivolol
Buy Nebivolol at AlgoRx →Nebivolol — interference & stacking
Predicted from mechanism, not from an interaction study. There are no trials of these combinations — what follows is what the biology implies, so treat it as a reason to watch something, not as a finding.
What Nebivolol moves on your bloodwork
These are the markers this compound is expected to move, and which direction. Knowing that in advance is mostly about NOT panicking: some of these moving is the compound working.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Potassium and creatinine are the two that matter, and a CMP has both. ACE inhibitors and ARBs raise potassium by reducing aldosterone, and they cause a small expected rise in creatinine when started — a rise under about 30% is haemodynamic and is not kidney damage.
What to do: Baseline, then again 1–2 weeks after starting or after any dose increase. That second draw is the one people skip and it is the one that matters. - Cystatin C with eGFR — ◆ worth watching
A better read of kidney filtration than creatinine if you carry a lot of muscle — creatinine-based eGFR reads falsely low on a muscular person and turns a normal kidney into a scary number.
What to do: Worth one measurement if creatinine-based eGFR looks borderline and you train hard. - Uric Acid — ↓ expected to fall
Losartan specifically is uricosuric — it lowers uric acid, which is a genuine and under-used advantage if gout is in the picture. This is NOT a class effect; the other ARBs do not do it.
What to do: Relevant only if you have gout or a high baseline urate.
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Get the complete breakdown for Nebivolol — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →Beta-blockers are a different mechanism to the two above and carry their own specific caution: never stop one abruptly. Rebound tachycardia and hypertension are well documented. They also blunt the adrenaline response, which masks the early warning signs of hypoglycaemia and flattens the training heart-rate response.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
Get the complete breakdown for Nebivolol — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →Bloodwork to run alongside Nebivolol
Run these before you start, and again after 8–12 weeks. A baseline you didn’t take is one you can never go back for.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 102 markers A–Z
Nebivolol — frequently asked questions
What is Nebivolol?
Nebivolol (Bystolic) is a longevity & bioregulators research compound. Highly beta-1 selective blocker that also stimulates nitric-oxide-mediated vasodilation — the only beta blocker with that second mechanism.
Is the full Nebivolol protocol on this page?
The reported research dose is on this page, along with how Nebivolol works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside the Academy.
What is the half-life of Nebivolol?
Nebivolol has an approximate half-life of ~10 hours (longer in poor CYP2D6 metabolisers), which is part of what determines how often it's dosed.
What's the evidence behind Nebivolol?
Current evidence level: Approved for hypertension; the favourable metabolic profile rests on smaller trials. Nebivolol is offered for research purposes only and is not an approved medicine.
Want Coach Cam's exact Nebivolol protocol?
Dosing schedules, stacking, cycle timing and my personal notes live inside the Academy — plus the full interactive Vault of 237 compounds & 350 supplements.
Join the Academy — $10/mo →What Nebivolol is used for
Nebivolol appears under 3 goals in the Vault’s goal router, grouped by the mechanism it works through rather than by how much trial evidence exists. Each link opens that pathway in full, with the alternatives beside it and the bloodwork that tests it.